(AOF) – The Transgene laboratory announces that it has received approval to initiate a Phase I study with TG6050, an IL-12-armed, intravenously-delivered oncolytic virus. This proprietary virus is from Transgene’s Invir.IO platform, which expresses interleukin 12 (IL-12) and an anti-CTLA4 antibody. The phase I study, called Delivir, will evaluate the intravenous (IV) administration of this innovative multifunctional immunotherapy in patients with non-small cell lung cancer.
This morning around 10, the Transgene share gained 2.51% to 1.79 euros.
TG6050 is expected to help overcome tumor resistance to treatment by initiating an anti-tumor response through a unique combination of actions including oncolysis (direct destruction of tumor cells following viral replication), induction of an immune response, and release of high concentrations of IL-12 and anti-CTLA4 antibodies in the tumor.
Intravenous administration significantly increases the therapeutic and market potential of this oncolytic. This targeted approach makes it possible to reach various cancerous lesions and metastases that are inaccessible with intratumor injection.
© AOF
Legal disclaimer
The AOF information reproduced on Capital.fr is taken from the AOF information service. This information is protected by intellectual property rights held by OPTION FINANCE SAS, publisher of the AOF real-time stock market information service, and its contributors. Consequently, any reproduction, copy, duplication, modification, transfer, redistribution, translation, commercial or non-commercial exploitation, creation of a hyperlink or reuse in any way of this information is subject to the prior written consent of OPTION FINANCE SAS and its contributors . AOF can be reached at the following address [email protected] OPTION FINANCE SAS collects your data from the sources it considers to be the most secure. However, except for its gross negligence, OPTION FINANCES SAS and its collaborators do not guarantee in any way the absence of errors and defects, even hidden ones, nor the completeness or lack of conformity for any use of this data and of OPTION FINANCE SAS or one of its collaborators, and cannot be held responsible for any delays or interruptions that could affect access to them. The user of the OPTION FINANCE SAS service will use the AOF data at his own risk and shall hold OPTION FINANCE SAS and its contributors harmless from any claim arising from such use.
Get our latest news
Every morning, the information to remember about financial markets.